PE20161344A1 - Determinantes de respuesta del cancer a la inmunoterapia - Google Patents
Determinantes de respuesta del cancer a la inmunoterapiaInfo
- Publication number
- PE20161344A1 PE20161344A1 PE2016000989A PE2016000989A PE20161344A1 PE 20161344 A1 PE20161344 A1 PE 20161344A1 PE 2016000989 A PE2016000989 A PE 2016000989A PE 2016000989 A PE2016000989 A PE 2016000989A PE 20161344 A1 PE20161344 A1 PE 20161344A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- composition
- determinants
- immunotherapy
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 102100026882 Alpha-synuclein Human genes 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923183P | 2014-01-02 | 2014-01-02 | |
| US201462066034P | 2014-10-20 | 2014-10-20 | |
| US201462072893P | 2014-10-30 | 2014-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161344A1 true PE20161344A1 (es) | 2016-12-23 |
Family
ID=53494217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000989A PE20161344A1 (es) | 2014-01-02 | 2014-12-23 | Determinantes de respuesta del cancer a la inmunoterapia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160326597A1 (OSRAM) |
| EP (1) | EP3090066A4 (OSRAM) |
| JP (1) | JP2017504324A (OSRAM) |
| KR (1) | KR20160102314A (OSRAM) |
| CN (1) | CN106164289A (OSRAM) |
| AU (1) | AU2014374020A1 (OSRAM) |
| BR (1) | BR112016015399A2 (OSRAM) |
| CA (1) | CA2935214A1 (OSRAM) |
| CL (1) | CL2016001708A1 (OSRAM) |
| MX (1) | MX2016008771A (OSRAM) |
| PE (1) | PE20161344A1 (OSRAM) |
| PH (1) | PH12016501329A1 (OSRAM) |
| RU (1) | RU2707530C2 (OSRAM) |
| SG (2) | SG11201605432RA (OSRAM) |
| WO (1) | WO2015103037A2 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CN106999582A (zh) | 2014-11-13 | 2017-08-01 | 约翰·霍普金斯大学 | 检查点阻断和微卫星不稳定性 |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CA2987730C (en) | 2015-04-08 | 2020-02-18 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| MX392028B (es) | 2015-05-13 | 2025-03-04 | Agenus Inc | Vacunas para el tratamiento y prevención del cáncer. |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| CN108701173A (zh) | 2015-10-12 | 2018-10-23 | 南托米克斯有限责任公司 | 用于发现预测对检查点抑制剂敏感的msi和新表位的系统、组合物和方法 |
| MX387275B (es) | 2015-10-12 | 2025-03-18 | Nantomics Llc | Neoepítopos virales y sus usos |
| KR20250161050A (ko) * | 2015-10-12 | 2025-11-14 | 난토믹스, 엘엘씨 | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 |
| EP3365000B1 (en) | 2015-10-23 | 2020-06-10 | Novartis AG | Method of deriving a value for percent biomarker positivity for selected cells present in a field of view |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| WO2017118702A1 (en) * | 2016-01-08 | 2017-07-13 | Vaccibody As | Neoepitope rna cancer vaccine |
| WO2017143092A1 (en) | 2016-02-19 | 2017-08-24 | Nant Holdings Ip, Llc | Methods of immunogenic modulation |
| WO2017151517A1 (en) * | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
| JP6821693B2 (ja) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | がんのための治療方法及び診断方法 |
| US12065699B2 (en) | 2016-03-15 | 2024-08-20 | Repertoire Genesis Incorporation | Monitoring and diagnosis for immunotherapy, and design for therapeutic agent |
| CA3010779A1 (en) * | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| SG11201810951RA (en) * | 2016-06-10 | 2019-01-30 | Io Therapeutics Inc | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| WO2018005276A1 (en) * | 2016-06-29 | 2018-01-04 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| WO2018057858A1 (en) | 2016-09-23 | 2018-03-29 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CN110418851A (zh) * | 2016-10-06 | 2019-11-05 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| JP2020507557A (ja) | 2016-12-01 | 2020-03-12 | ナントミクス，エルエルシー | 腫瘍抗原性の処理および提示 |
| US11480572B2 (en) | 2016-12-16 | 2022-10-25 | Nantbio, Inc. | Live cell imaging systems and methods to validate triggering of immune response |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| CA3056700A1 (en) * | 2017-03-17 | 2018-09-20 | Nantomics, Llc | Liquid biopsy for cfrna |
| WO2018183928A1 (en) * | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| KR102396784B1 (ko) * | 2017-06-13 | 2022-05-13 | 보스턴진 코포레이션 | 분자 기능적 프로파일을 생성하고, 시각화하고, 분류하는 시스템 및 방법 |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| SG11202002282TA (en) | 2017-09-20 | 2020-04-29 | Regeneron Pharma | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
| EP3688165A4 (en) | 2017-09-25 | 2021-09-29 | Nant Holdings IP, LLC | VALIDATION OF THE PRESENTATION OF NEOEPITOPES |
| BR112020005602A2 (pt) * | 2017-09-25 | 2020-10-13 | Memorial Sloan Kettering Cancer Center | carga de mutação de tumor |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CA3079253A1 (en) | 2017-11-03 | 2019-05-09 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| EP3707272A4 (en) * | 2017-11-09 | 2021-11-24 | The Trustees of The University of Pennsylvania | EXTRACELLULAR VESICULAR PROTEINS AND THEIR USE FOR CANCER DIAGNOSIS, PREDICTION OF RESPONSE TO THERAPY AND TREATMENT |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| WO2019109086A1 (en) | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技（上海）有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| CA3096909A1 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| CA3107983A1 (en) | 2018-07-23 | 2020-01-30 | Guardant Health, Inc. | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
| KR20210052511A (ko) | 2018-08-31 | 2021-05-10 | 가던트 헬쓰, 인크. | 무세포 dna에서의 미세부수체 불안정성 검출 |
| CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院（同济大学附属东方医院） | 一种hla-0201限制性padi4表位多肽及其应用 |
| EP3893932A4 (en) * | 2018-12-12 | 2022-09-07 | Medimmune, LLC | BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER |
| SG11202106708VA (en) * | 2018-12-21 | 2021-07-29 | Agency Science Tech & Res | Method of predicting for benefit from immune checkpoint inhibition therapy |
| US12031181B2 (en) | 2019-04-05 | 2024-07-09 | Illumina, Inc. | Quantitative score of HLA diversity |
| US20200371103A1 (en) * | 2019-05-24 | 2020-11-26 | Iuve, Inc. | Precision Medicine Method for Cancer Immunotherapy |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER |
| NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4000595A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| EP4000596A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| US20240192195A1 (en) * | 2021-04-10 | 2024-06-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
| CN117999355A (zh) | 2021-08-24 | 2024-05-07 | 生物技术欧洲股份公司 | 体外转录技术 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024216165A1 (en) | 2023-04-12 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Computational methods for selecting personalized neoantigen vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| CA2585776A1 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| WO2008109075A2 (en) * | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| DK3023788T3 (da) * | 2010-05-14 | 2020-04-27 | Massachusetts Gen Hospital | Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Withdrawn
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en not_active Ceased
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015103037A3 (en) | 2015-11-05 |
| MX2016008771A (es) | 2016-12-20 |
| RU2016131207A3 (OSRAM) | 2018-06-22 |
| US20160326597A1 (en) | 2016-11-10 |
| RU2707530C2 (ru) | 2019-11-27 |
| BR112016015399A2 (pt) | 2017-10-24 |
| EP3090066A2 (en) | 2016-11-09 |
| WO2015103037A2 (en) | 2015-07-09 |
| EP3090066A4 (en) | 2017-08-30 |
| SG10201805674YA (en) | 2018-08-30 |
| JP2017504324A (ja) | 2017-02-09 |
| AU2014374020A1 (en) | 2016-08-18 |
| PH12016501329A1 (en) | 2016-10-03 |
| KR20160102314A (ko) | 2016-08-29 |
| CL2016001708A1 (es) | 2017-03-17 |
| CN106164289A (zh) | 2016-11-23 |
| RU2016131207A (ru) | 2018-02-07 |
| CA2935214A1 (en) | 2015-07-09 |
| SG11201605432RA (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161344A1 (es) | Determinantes de respuesta del cancer a la inmunoterapia | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
| SA519401072B1 (ar) | Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها | |
| PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| PE20170289A1 (es) | Anticuerpos anti tigit | |
| CO2017007619A2 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| MX389021B (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
| MX375800B (es) | Anticuerpos humanizados contra cd269 (bcma). | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| MX2015013104A (es) | Composiciones y métodos para la inmunoterapia. | |
| PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела |